Novo Nordisk cuts US list prices ~50% for 2027, retatrutide hits record 28.7% weight loss in Phase 3, and experts propose 10-year GLP-1 cancer trial.
10 stories · Covering industry, clinical-trials, research, regulatory
Today's peptide news is dominated by a major pricing shakeup, groundbreaking clinical trial data, and rising global regulatory scrutiny. Novo Nordisk announced it will slash U.S. list prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting 2027, while Eli Lilly's retatrutide posted a record 28.7% weight loss in Phase 3 TRIUMPH-4 and a new competitor — Novo's UBT251 triple agonist — delivered 19.7% weight loss in just 24 weeks. Meanwhile, a global expert panel proposed an unprecedented 10-year trial to test whether GLP-1 drugs can prevent obesity-related cancers, and UK MPs heard alarming testimony that black market GLP-1 profit margins now rival those of cocaine and heroin.
Novo will reduce prices to $675/month starting January 1, 2027 — approximately 50% cut for Wegovy and 35% for Ozempic, aimed at patients on high-deductible plans.
Eli Lilly's triple-agonist achieved record weight loss at the highest dose with substantial reductions in knee osteoarthritis pain. Seven more Phase 3 trials expected in 2026.
Novo Nordisk and United Laboratories' new triple agonist achieved 19.7% weight loss in 24 weeks vs 2.0% placebo, intensifying competition with retatrutide.
A panel of 21 obesity and cancer experts proposed a 5,000-participant, decade-long trial to test whether semaglutide and tirzepatide can prevent obesity-related cancers.
The MHRA told Parliament that 81,000 doses have been seized in three years, with illegal GLP-1 profit margins rivaling class A drugs.
Retrospective study found combining CGRP monoclonal antibodies with gepants is a safe and well-tolerated dual-mechanism migraine prevention approach.
Mordor Intelligence reports the global peptide therapeutics market valued at $49.68B in 2026, projected to reach $70.2B by 2031 driven by cancer, metabolic disorders, and oral delivery advances.
Retrospective cohort study showed significant migraine frequency reduction with favorable safety for patients with comorbid MS taking CGRP-targeted treatments.
About 1 in 8 US adults now report taking a GLP-1 drug per KFF. Experts caution effects are larger and longer-lasting when combined with lifestyle changes.
New data shows GLP-1 adherence drops significantly after the first year, with cost as a major factor. Insurance gaps and lack of mandated weight loss coverage pose barriers.